International Conference of Marxist–Leninist Parties and Organizations (International Newsletter)

Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma

Retrieved on: 
Thursday, June 15, 2023
Antigen, CT, TCL, PRS, Perforin-1, ALC, Neoplasm, ICML, Infection, ITK, Lymphoma, Clinical trial, T-cell lymphoma, Research, RNA, Publication, Immunotherapy, Granzyme, CD8, International Conference of Marxist–Leninist Parties and Organizations (International Newsletter), B-cell lymphoma, Patient, Blood, CR, Biology, Poster, CD4, FDA, Tumor microenvironment, Conference, PR, Safety, Pharmaceutical industry, Vaccine, Medical imaging, Corvus

BURLINGAME, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced new data for CPI-818, the Company’s ITK inhibitor, demonstrating the potential to treat a variety of solid and hematological cancers based on a novel immunotherapy mechanism of action. The data includes updated interim results from the CPI-818 Phase 1/1b clinical trial that continues to demonstrate the potential of ITK inhibition and the absolute lymphocyte count (ALC) biomarker in T cell lymphoma (TCL). The data is being presented in a poster at the International Conference on Malignant Lymphoma (ICML) meeting, which is taking place June 13-17, 2023 in Lugano, Switzerland.

Key Points: 
  • The data includes updated interim results from the CPI-818 Phase 1/1b clinical trial that continues to demonstrate the potential of ITK inhibition and the absolute lymphocyte count (ALC) biomarker in T cell lymphoma (TCL).
  • The data is being presented in a poster at the International Conference on Malignant Lymphoma (ICML) meeting, which is taking place June 13-17, 2023 in Lugano, Switzerland.
  • “The preclinical and clinical data indicate a consistent and comprehensive rationale based on the biology and mechanism of immune enhancement resulting from selective ITK inhibition.
  • We see this in the interim tumor response data, which showed that a majority of the patients treated with the optimal dose of 200mg twice per day of CPI-818 experience tumor regression.